

■ Time Table  
Day 1, July 18 (Thu)

7月2日現在

		7	8	9	10	11	12	13	14	15	16	17	18	19				
Kyoto International Conference Center	Main Hall	1F	Opening Remarks	O1-1 Hematologic Malignancies	O1-2 Head and Neck Cancer	MeS-1 Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus in daily practice	PS1 Presidential Session 1	O1-3 Lung Cancer/Thoracic Cancer1 (Lung Cancer1)	O1-4 Lung Cancer/Thoracic Cancer2 (Lung Cancer2)	ES-1 New Treatment Option for refractory DLBCL -CAR-T cell therapy-								
	Annex 1	1F	EL1 Translational Research Based on Molecular Pathology of Cancer	EL2 Introduction to the Basics of Tumor Biology II	EL3 The Overview of Molecular Analyses and Companion Diagnostics	EL4 Recent Findings in Tumor Immunology	EL5 Clinical Pharmacology of Anticancer Drugs and Theory of Chemotherapy	MeS-2 The first year of REIWA Beginning of the new NSCLC treatments	EL6 Cytotoxic Anticancer Agents	EL7 Categories and Characteristics of Molecular Targeting Agents	EL8 Management of Adverse Events and Supportive Care of Cancer Chemotherapy	EL9 Oncologic Emergency / Paraneoplastic Syndrome	EL10 Cancer therapy for geriatric patients	EL11 Update of Palliative Medicine in Oncology	EL12 Psycho-Oncology, Advance Care Planning	EL13 Conflict of Interest	EL14 Act on the Protection of Personal Information and Clinical Trial Act	ES-2 Precision oncology based on genome biomarkers
	Annex2	1F	SY1 The Challenge of Translational Research	ES 9:00-11:00	EL15 Anti-cancer Drugs for Head and Neck Cancer and Thyroid Cancer	MeS-3 The treatment strategy and practices for MSI-High GI cancers	SY2 Treatment Development Through Investigator-initiated Registration-directed Trials and the Advanced Medical Care System in Japanese Cancer Cooperative Groups	O1-5 Translational Research	MO1-1 Gynecologic Cancer	ES-3 What is the best practice in the treatment of metastatic brain tumor?								
	Room A	2F	SY3 Clinical Trial in Supportive and Palliative Care	9:00-11:00	MeS-4 2019: A paradigm shift in testing & treatment of NSCLC harboring EGFR mutation	PD1 The Role of Multidisciplinary Staffs on the Support to Decision Making for Patients with Cancer	O1-6 Patient Advocacy/ Survivorship	O1-7 Palliative Care/ Symptom Management	ES-4 Treatment strategy for advanced or metastatic soft tissue sarcoma									
	Room B-1	2F	MO1-2 Rare Cancer 1	ES 9:00-9:50	MO1-3 Rare Cancer2	ES 9:50-10:40	MO1-4 Patient Advocacy/ Survivorship	ES 10:40-11:30	PS1 Presidential Session 1 (relay)	MO1-5 Hepatobiliary/Pancreatic Cancer1 (Liver Cancer)	ES 15:40-16:30	MO1-6 Hepatobiliary/Pancreatic Cancer2 (Gallbladder and Biliary Tract Cancer/Pancreatic Cancer)	ES 16:30-17:20	MO1-7 Translational Research1	ES 17:20-18:10	ES-5 Liquid Biopsies and Cancer Genomic Profiling		
	Room D	1F	MS1 Development of Combination Therapy Using I-O Agent for Upper GI Tract Cancer	ES 9:00-10:30	MeS-5 Immunotherapy of OML and immunological characteristics of therapy response	MeS-6 Immunotherapy of OML and immunological characteristics of therapy response	SY4 New Evidences of Chemotherapy in Biliary Tract and Pancreatic Cancers and Introduction them to the Practice	MO1-11 Clinical Trial Facilitation Program	MO1-12 Multidisciplinary Team Program1	MO1-13 Multidisciplinary Team Program2	ES-6 Cancer treatment and cancer pain treatment for cancer patients							
	Room E	1F	MO1-8 Breast Cancer1	ES 9:00-9:50	MO1-9 Genitourinary Cancer	ES 9:50-10:40	MO1-10 Lung Cancer/ Thoracic Cancer1 (NSCLC/Others1)	ES 10:40-11:30	MS2 How to Integrate Molecular Biomarker in Clinic for CRC?	O1-8 Breast Cancer 1	ES 15:20-16:55	O1-9 Breast Cancer2	ES 16:55-18:10	ES-7 The role of pharmacist and nurse for management of febrile neutropenia				
	Sakura	1F	AJS ASCO/JSMO Joint Symposium Precision Oncology: How Do We Use a Panel Gene Test?	ES 9:00-11:00	MeS-7 HER2 positive breast cancer ~Therapeutic strategies for EBC and MBC~	ES 11:40-12:30	MeS-8 Lung cancer: Prospects for Cure	PSY1 Regulatory Science in an Era of Precision Medicine	ES 13:40-15:40	EJS ESMO/JSMO Joint Symposium Hereditary Cancer Treatment in Cancer Genome Era	ES 15:40-17:40	ES-8 The world of biomarkers in immune checkpoint inhibitors						
	Swan	1F	MO1-14 Gastrointestinal Cancer1	ES 9:00-9:50	MO1-15 Gastrointestinal Cancer2	ES 9:50-10:40	MO1-16 Gastrointestinal Cancer3 (Colorectal Cancer1)	ES 10:40-11:30	MeS-9 Landscape of Diagnosis in NSCLC and Therapeutic Strategy in EGFR mutation positive Lung Cancer	MO1-17 Gastrointestinal Cancer4 (Esophageal Cancer)	ES 13:40-14:30	MO1-18 Gastrointestinal Cancer5 (Gastric Cancer1)	ES 14:30-15:20	MO1-19 Gastrointestinal Cancer6 (Gastric Cancer2)	ES 15:20-16:10	SPS1 A New Approach to Summarizing Treatment Effects: Are Conventional Methods for Analyzing OS and PFS Always Appropriate?	ES-9 Anti-cancer therapy coordinating with a wide variety of healthcare experts at Shizuoka Cancer Center - Working as 'One Team'	
Grand Prince Hotel Kyoto	Royal Room	1F	PSY2 Future Tracks of Clinical Oncology and Development in South-East Asia	ES 9:00-11:30	MeS-10 The latest findings in the treatment of ER-positive HER2-negative MBC	PSY3 Issues and Perspectives for Genomic Medicine in Oncology in General Hospitals	ES 14:10-16:10	JS1 Joint Symposium 1 (JASTRO/JSMO) Role of Radiation Therapy in Cancer Patients	ES 16:10-18:10	ES-10 Treatment strategy for advanced stage follicular lymphoma ~drug selection and management of adverse events~								
	Rose Room	B1F	WS1 How Do We Properly Use Various Regimens in Chemotherapy for Advanced HCC?	ES 9:20-10:50	MeS-11 Medical treatment for advanced prostate cancer: an updated overview of current strategies and therapeutic agents	SY5 Immune Therapy for Hematologic Malignancies	ES 14:10-16:10	JS2 Joint Symposium 2 on Rare Cancers in Asia (JCA/JSCO/JSMO/RCU) Rare Cancer in Asia: Current Status and Construction of Medical Network	ES 16:10-18:10	ES-11 A feedback from the Consensus meeting 2018 with Western Medical Oncologists and Dermatologists: Tips for precise understanding of drug and drug action related with immune checkpoint inhibitor (ICI)								
	Gold Room	B2F	SY6 Cancer Immunotherapy: A Paradigm Shift in the First-line Treatment of Lung Cancer	ES 9:00-11:00	MeS-12 Treatment strategy for 2nd line in unresectable and recurrent gastric cancer	JS3 Joint Symposium 3 (JCS/JSMO) Cardio-Oncology Learned from Case Discussion	ES 14:10-16:10	SY7 Future Prospects of Immune Checkpoint Inhibitors	ES 16:10-18:10	ES-12 Clinical usefulness of the anti-PD-1, avelumab / Management of colitis as irAE								
Kyoto International Conference Center	Room C-1	1F	DL Landscape of Diagnosis in NSCLC and Therapeutic Strategy in EGFR mutation positive Lung Cancer	ES 11:40-12:30	MeS-13 What's the best sequence therapy for EGFR-mutant NSCLC?	MeS-14 Cancer genomes of 5000 Japanese patients ~oncogenic processes and oncogene application-	ES 11:40-12:30	MO1-20 Translational Research8	ES 17:00-17:50	ES-13 Patient-Centered Team Oncology Based on Evidence								
	Room C-2	1F	DL2 Precision Medicine in Triple Negative Breast Cancer: The Future is Coming	ES 10:30-11:20	MeS-14 Cancer genomes of 5000 Japanese patients ~oncogenic processes and oncogene application-	ES 11:40-12:30	DL1 My Lung Cancer World: Yesterday, Today and Tomorrow	ES 17:10-18:00	ES-14 Which regimen do you prefer for mCRC 1st line chemotherapy: Oxaliplatin-based, Irinotecan-based or Triplet regimen?									
	Room B-2	2F	DL2 Precision Medicine in Triple Negative Breast Cancer: The Future is Coming	ES 10:30-11:20	DL3 Breast Cancer in Young and Premenopausal Women	ES 14:10-15:00	DL4 Checkpoint Inhibition and Other Immunotherapies in the Management of Sarcomas: Are We There Yet?	ES 15:10-16:00	DL5 Challenges of Current Management in Nasopharyngeal Carcinoma from a Perspective of a High Incidence Developing Country	ES 16:10-17:00	DL6 International Collaboration in Cancer Clinical Trials: The Australian Gastrointestinal Cancer Trials Group Experience	ES 17:10-18:00						
	Room 104 (Meet the Experts)	1F	ME1 Targeting Biliary Tract Cancers	ES 9:00-10:00	ME2 Evolving Strategies for Enhancing the Impact of Immunotherapy in Breast Cancer	ES 10:00-11:00	ME3 Frailty and Challenges of Immunotherapy in Older Patients	ES 14:10-15:10	ME4 New Therapeutic Strategies for EGFR Mutant Lung Cancer	ES 15:10-16:10	ME5 Development of Immunotherapy in Gastro-esophageal Cancer in the Worldwide Arena	ES 16:10-17:10	ME6 Treatment Strategies for Newly Diagnosed Elderly Patients with Multiple Myeloma	ES 17:10-18:10				
	Room 510 (Patient Advocate Program)	5F	PAP オリエンテーション	ES 9:30-10:00	PAP 日本のがん対策 ~これまでと、これから~	ES 10:10-11:00	PAP ランチョンセミナー 癌禍のいづく治療を導くために ~シェアードセッション/メイキング~	ES 11:40-12:30	PAP がんサバイバーシップとアドボカシー	ES 13:00-13:50	PAP がんと暮らしを支える制度	ES 14:00-14:50	IPAP 私たちの患者会活動 (患者会からの発表)	ES 15:00-16:30				
Event Hall-New Hall (Poster Area)	1F	Putting up posters	ES 9:00-10:00	Poster Display	ES 10:00-12:40	Poster Session	ES 12:40-13:35	Poster Display	ES 13:35-18:10	Poster removal	ES 18:10-19:10							

**Explanatory Notes**

- SPS =Special Presidential Session
- PS =Presidential Session
- AJS =ASCO/JSMO Joint Symposium
- EJS =ESMO/JSMO Joint Symposium
- JS =Joint Symposium
- PSY =Presidential Symposium
- SY =Symposium
- MS =Mini Symposium
- PD =Panel Discussion
- WS =Workshop
- EL =Educational Lecture
- DL =Distinguished Expert Lecture
- ME =Meet the Experts
- MeS =Medical Seminar
- ES =Evening Seminar
- O =Oral Abstract Session
- MO =Mini-Oral Abstract Session
- P =Poster
- Simultaneous Interpretation (E&J)
- English Session